AtriCure (ATRC) Q2 Revenue Jumps 17%
(NASDAQ:ATRC), a medical device company specializing in cardiac surgical technologies, delivered its earnings release on July 29, 2025, reporting results that outpaced Wall Street consensus estimates. The company posted revenue of $136.1 million (GAAP), ahead of the $130.2 million analyst estimate (GAAP), and a non-GAAP loss per share of $(0.02), a substantial improvement from $(0.17) a year ago and handily above expectations (non-GAAP). The period saw strong momentum in open ablation, appendage management, and pain management product lines. However, the minimally invasive (MIS) ablation segment in the U.S. continued to decline, offsetting some of the positive results. Overall, the quarter was marked by robust adoption of new devices and expanding geographic reach, prompting management to raise its financial outlook for the year.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
AtriCure operates in the medical devices sector, focusing on treatments for atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management. Its product portfolio includes cardiac ablation systems used in heart surgery, specialized devices for closing the left atrial appendage, and cryoablation probes for pain control after thoracic surgery. These technologies aim to improve outcomes for patients undergoing complex cardiac and thoracic procedures.
Source Fool.com
Atricure Inc. Stock
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 42 € shows a positive potential of 33.76% compared to the current price of 31.4 € for Atricure Inc..
